On February 6, Huadong Medicine Co.Ltd(000963) announced that Sinclair, its wholly-owned subsidiary in the UK, acquired 100% equity of viora, an energy source medical and beauty device company.
Public information shows that viora company, founded in 2005 and headquartered in New York, is an international medical beauty company focusing on medical beauty non-invasive and minimally invasive energy source equipment. It has core, SVC, PCR and other technologies, and has an advanced product portfolio using laser, intense pulsed light, RF, high-pressure jet, microcrystalline dermabrasion and other technologies to provide high-quality Cost effective non-invasive and minimally invasive solutions. The products are used in anti-aging, body and face shaping and other fields. Viora has sales operations in more than 60 countries / regions around the world, with more than 10000 global institutional users.
At present, viora mainly has five listed energy source medical and beauty equipment products, including reactiontm for body and face shaping and skin firming, and “V-series” products of medical and beauty multifunctional operation platform integrating radio frequency (RF), intense pulsed light (IPL), laser and other energy sources.
Huadong Medicine Co.Ltd(000963) said that it has preliminarily formulated its market strategy in China according to viora’s existing products. It is worth mentioning that Huadong Medicine Co.Ltd(000963) proposed the concept of “V women tech” for the first time, using the world’s advanced medical and aesthetic technology to focus on the field of women’s scientific and technological nursing and create a high-end product pipeline.
Huadong Medicine Co.Ltd(000963) said that this transaction is another important global strategic layout of Sinclair in the field of medical and American energy source equipment after the wholly-owned acquisition of Spanish energy source medical and American equipment company hightech in February 2021. Viora’s existing technologies and products such as intense pulsed light, microcrystalline dermabrasion and high-pressure jet are effectively complementary to sinclairebd’s business product pipeline, realizing the full layout of energy source medical and American device products and basically realizing the coverage of mainstream technologies of energy source devices.
Huadong Medicine Co.Ltd(000963) said that after the acquisition, the Spanish and Bulgarian teams of sinclairebd business will effectively integrate with the existing management, production, R & D and other departments of viora company to further improve the operation and management efficiency of sinclairebd business. Viora’s brand reputation accumulated in the U.S. market, perfect market service staffing, complete marketing management system and extensive market resources will also become an effective entry point for sinclairebd’s business to further expand the U.S. market.
According to statistics, after the completion of this transaction, Huadong Medicine Co.Ltd(000963) will have more than 30 products in the field of non-invasive + minimally invasive medical beauty all over the world, including 20 products listed at home and abroad and more than 10 global innovative products under research. The product portfolio covers non-surgical mainstream medical beauty fields such as facial filling, catgut embedding, skin management, body shaping, hair removal and private repair, A comprehensive product cluster has been formed, with the number and coverage of products in the forefront of the industry. Among them, a number of potential products are expected to be listed and sold at home and abroad in 2022, which will bring new growth momentum to the company’s global medical and American business.
Lv Liang, chairman of Huadong Medicine Co.Ltd(000963) said: “This transaction further expands the company’s innovative product pipeline of medical beauty, which is in line with the company’s international development strategy of medical beauty, and helps to continuously consolidate and enhance the company’s comprehensive competitiveness in the field of medical beauty. In the future, the company will continue to make steady progress in accordance with the established strategy of ‘global operation layout, double cycle operation and development’, and strengthen Sinclair, a wholly-owned subsidiary of the UK, as the global medical beauty The international industrial expansion of the operation center adheres to the diversified business models such as independent research and development, external cooperation and equity investment, and successively introduces the world-class medical and American products with high scientific and technological gold content into China. It adheres to the self-supporting model and relies on the company’s professional clinical registration and marketing promotion team to help the rapid commercialization of international high-quality products. Gradually realize the company’s global strategic layout of medical beauty, and strive to build Sinclair into a world-class high-end innovative medical beauty enterprise. “
